B. Freidlin

Most-cited papers

1. Biomarker enrichment strategies: matching trial design to biomarker credentials

   B. Freidlin, E. Korn

   2014Nature Reviews Clinical Oncology174 citations

   Semantic Scholar

   Save

2. Statistical and practical considerations for clinical evaluation of predictive biomarkers.

   M. Polley, B. Freidlin, E. Korn, B. Conley +2 more

   2013Journal of the National Cancer Institute140 citations Open access

   Semantic Scholar

   Save

3. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

   E. Korn, B. Freidlin, J. Abrams

   2011Journal of Clinical Oncology133 citations Open access

   Semantic Scholar

   Save

4. Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

   B. Freidlin, E. Korn

   2019Journal of Clinical Oncology88 citations Open access

   Semantic Scholar

   Save

5. Randomized phase II trial designs with biomarkers.

   B. Freidlin, L. McShane, M. Polley, E. Korn

   2012Journal of Clinical Oncology80 citations Open access

   Semantic Scholar

   Save

6. Borrowing Information Across Subgroups in Phase II Trials: Is It Useful?

   B. Freidlin, E. Korn

   2013Clinical Cancer Research75 citations Open access

   Semantic Scholar

   Save

7. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements

   E. Korn, B. Freidlin

   2017Journal of the National Cancer Institute74 citations Open access

   Semantic Scholar

   Save

8. Platform Trials — Beware the Noncomparable Control Group

   Lori E. Dodd, B. Freidlin, E. Korn

   2021New England Journal of Medicine73 citations Open access

   Semantic Scholar

   Save

9. Design issues in randomized phase II/III trials.

   E. Korn, B. Freidlin, J. Abrams, S. Halabi

   2012Journal of Clinical Oncology62 citations Open access

   Semantic Scholar

   Save

10. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

    Shaji K. Kumar, L. Baizer, N. Callander, S. Giralt +12 more

    2022Blood Cancer Journal60 citations Open access

    Semantic Scholar

    Save

11. Statistical Challenges in the Evaluation of Treatments for Small Patient Populations

    E. Korn, L. McShane, B. Freidlin

    2013Science Translational Medicine56 citations

    Semantic Scholar

    Save

12. Phase III clinical trials that integrate treatment and biomarker evaluation.

    B. Freidlin, Zhuo-Xin Sun, R. Gray, E. Korn

    2013Journal of Clinical Oncology51 citations Open access

    Semantic Scholar

    Save

13. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

    F. Meric-Bernstam, J. Ford, P. O'Dwyer, G. Shapiro +19 more

    2023Clinical Cancer Research48 citations Open access

    Semantic Scholar

    Save

14. Marker Sequential Test (MaST) Design

    B. Freidlin, E. Korn, R. Gray

    2013Clinical Trials45 citations Open access

    Semantic Scholar

    Save

15. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

    Y. Lawrence, B. Vikram, J. Dignam, A. Chakravarti +8 more

    2013Journal of the National Cancer Institute45 citations Open access

    Semantic Scholar

    Save

16. Methodology for comparative effectiveness research: potential and limitations.

    E. Korn, B. Freidlin

    2012Journal of Clinical Oncology38 citations

    Semantic Scholar

    Save

17. Dose Optimization During Drug Development: Whether and When To Optimize.

    E. Korn, J. Moscow, B. Freidlin

    2022Journal of the National Cancer Institute34 citations Open access

    Semantic Scholar

    Save

18. NCI-RTOG Translational-Program Strategic Guidelines for the Early Stage Development of Radiosensitizers

    Y. Lawrence, B. Vikram, J. Dignam, A. Chakravarti +6 more

    201232 citations

    Semantic Scholar

    Save

19. Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?

    B. Freidlin, E. Korn

    2017Journal of the National Cancer Institute31 citations Open access

    Semantic Scholar

    Save

20. An audit strategy for progression-free survival

    Lori E. Dodd, E. Korn, B. Freidlin, R. Gray +1 more

    2011Biometrics27 citations Open access

    Semantic Scholar

    Save

21. Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.

    E. Korn, B. Freidlin

    2018Journal of Clinical Oncology24 citations Open access

    Semantic Scholar

    Save

22. Non-factorial analyses of two-by-two factorial trial designs

    E. Korn, B. Freidlin

    2016Clinical Trials22 citations

    Semantic Scholar

    Save

23. Design Issues in Randomized Clinical Trials of Maintenance Therapies.

    B. Freidlin, R. Little, E. Korn

    2015Journal of the National Cancer Institute22 citations Open access

    Semantic Scholar

    Save

24. Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report

    E. Korn, B. Freidlin

    2011American Journal of Bioethics22 citations

    Semantic Scholar

    Save

25. Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies

    E. Korn, B. Freidlin

    2017Annals of Oncology20 citations Open access

    Semantic Scholar

    Save

26. Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)

    Yixuan Zhao, Ying Yuan, E. Korn, B. Freidlin

    2023Clinical Cancer Research19 citations

    Semantic Scholar

    Save

27. Comparison of futility monitoring guidelines using completed phase III oncology trials

    Qiang Zhang, B. Freidlin, E. Korn, S. Halabi +2 more

    2016Clinical Trials19 citations Open access

    Semantic Scholar

    Save

28. Augmenting Randomized Clinical Trial Data with Historical Control Data: Precision Medicine Applications.

    B. Freidlin, E. Korn

    2022Journal of the National Cancer Institute18 citations Open access

    Semantic Scholar

    Save

29. Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

    R. Little, M. Othus, S. Assouline, S. Ansher +29 more

    2022Blood16 citations Open access

    Semantic Scholar

    Save

30. Are restricted mean survival time methods especially useful for Noninferiority Trials?

    B. Freidlin, Chen Hu, E. Korn

    2021Clinical Trials16 citations Open access

    Semantic Scholar

    Save

31. Adaptive randomization versus interim monitoring.

    B. Freidlin, E. Korn

    2013Journal of Clinical Oncology16 citations

    Semantic Scholar

    Save

32. Reply to Y. Yuan et al

    E. Korn, B. Freidlin

    201115 citations Open access

    Semantic Scholar

    Save

33. Commentary on Hey and Kimmelman

    E. Korn, B. Freidlin

    2015Clinical Trials14 citations

    Semantic Scholar

    Save

34. Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation.

    M. Polley, E. Korn, B. Freidlin

    2019JCO Precision Oncology13 citations Open access

    Semantic Scholar

    Save

35. Information time scales for interim analyses of randomized clinical trials

    B. Freidlin, M. Othus, E. Korn

    2016Clinical Trials12 citations

    Semantic Scholar

    Save

36. Time trends with response-adaptive randomization: The inevitability of inefficiency

    E. Korn, B. Freidlin

    2022Clinical Trials11 citations

    Semantic Scholar

    Save

37. Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?

    B. Freidlin, C. Allegra, E. Korn

    2019Journal of the National Cancer Institute11 citations Open access

    Semantic Scholar

    Save

38. Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017.

    Jared C. Foster, B. Freidlin, C. Kunos, E. Korn

    2019Journal of the National Cancer Institute11 citations Open access

    Semantic Scholar

    Save

39. Assessing treatment efficacy in the subset of responders in a randomized clinical trial

    E. Korn, M. Othus, T. Chen, B. Freidlin

    2017Annals of Oncology11 citations Open access

    Semantic Scholar

    Save

40. Sample size adjustment designs with time-to-event outcomes: A caution

    B. Freidlin, E. Korn

    2017Clinical Trials11 citations

    Semantic Scholar

    Save

41. Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?

    E. Korn, B. Freidlin

    2018Clinical Cancer Research10 citations Open access

    Semantic Scholar

    Save

42. Assessing causal relationships between treatments and clinical outcomes: always read the fine print

    B. Freidlin, E. Korn

    2012Bone Marrow Transplantation10 citations Open access

    Semantic Scholar

    Save

43. Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials

    Laura M. Yee, L. McShane, B. Freidlin, M. Mooney +1 more

    2019Cancer Journal8 citations Open access

    Semantic Scholar

    Save

44. RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

    B. Freidlin, E. Korn

    2016Journal of the National Cancer Institute8 citations Open access

    Semantic Scholar

    Save

45. Bias, Operational Bias, and Generalizability in Phase II/III Trials.

    B. Freidlin, E. Korn, J. Abrams

    2018Journal of Clinical Oncology7 citations Open access

    Semantic Scholar

    Save

46. Evaluation of chemoresponse assays as predictive markers

    E. Korn, B. Freidlin

    2015British Journal of Cancer7 citations Open access

    Semantic Scholar

    Save

47. Two-to-One Randomization: Rarely Advisable

    B. Freidlin, E. Korn

    2024JCO Oncology Practice6 citations

    Semantic Scholar

    Save

48. Reply to H. Uno et al and B. Huang et al.

    B. Freidlin, E. Korn

    2020Journal of Clinical Oncology6 citations

    Semantic Scholar

    Save

49. Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity

    Jared C. Foster, B. Freidlin, E. Korn, Malcolm A. Smith

    2020ESMO Open6 citations Open access

    Semantic Scholar

    Save

50. Myeloma Minimal Residual Disease and Surrogacy.

    R. Little, L. McShane, B. Freidlin

    2017JAMA Oncology6 citations

    Semantic Scholar

    Save